Press Releases
Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Regeneron Pharmaceuticals, Inc. announced that the EC has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S. and Ronapreve™ in the European Union (EU) and other countries. The EC granted marketing authorization for the antibody...
Drug Research
AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025
AbbVie and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research.
To date, the collaboration has led to novel insights related to biomarkers and therapeutic applications for existing AbbVie programs. This has...
Clinical Trials
Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1
During the 8-month assessment period there were 0 hospitalizations...
Press Releases
India sees sizable improvement in finished dosage reputation and growth ahead of CPhI India 2021
CPhI & P-MEC India – organised by Informa Markets – is set to welcome attendees and exhibitors from around the world, both online and in-person, as new CPhI analysis points to sustained pharma growth in India, with an improving...
Press Releases
Beximco Pharma introduces world’s first generic molnupiravir, an oral antiviral drug for COVID-19 treatment
Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the launch of the world's first generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme (MSD) and...
Drug Research
Biognosys Launches Next-Generation Blood Biomarker Discovery Solution
Biognosys, a leader in proteomics solutions for drug discovery and development, announces the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service. The service is designed to help researchers decipher the...
Drug Research
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec® ODT in the U.S., and is indicated for the acute...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















